sapanisertib (CB-228)

News alerts, weekly reports and conference planners

Company:

Calithera

Drug class:

mTORC1 inhibitor, mTORC2 inhibitor

Related drugs:

NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B	CB-228 Sensitive: B - Late Trials CB-228 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	KEAP1 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
NFE2L2 mutation	Lung Cancer	NFE2L2 mutation	Lung Cancer	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2	CB-228 Sensitive: C2 – Inclusion Criteria CB-228 Sensitive : C2
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3	tamoxifen + CB-228 Sensitive: C3 – Early Trials tamoxifen + CB-228 Sensitive : C3
NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	NFE2L2 E79K	Lung Non-Small Cell Squamous Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
EWSR1-POU5F1 fusion	Renal Cell Carcinoma	EWSR1-POU5F1 fusion	Renal Cell Carcinoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
AKT1 mutation + mTOR mutation	Leiomyosarcoma	AKT1 mutation + mTOR mutation	Leiomyosarcoma	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
PTEN deletion	Renal Cell Carcinoma	PTEN deletion	Renal Cell Carcinoma	CB-228 Resistant: C3 – Early Trials CB-228 Resistant : C3	CB-228 Resistant: C3 – Early Trials CB-228 Resistant : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + CB-228 Sensitive: C3 – Early Trials osimertinib + CB-228 Sensitive : C3	osimertinib + CB-228 Sensitive: C3 – Early Trials osimertinib + CB-228 Sensitive : C3
KEAP1 mutation	Lung Adenocarcinoma	KEAP1 mutation	Lung Adenocarcinoma	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3
KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3
NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	NFE2L2 mutation	Lung Non-Small Cell Squamous Cancer	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3	CB-228 + CB-839 Sensitive: C3 – Early Trials CB-228 + CB-839 Sensitive : C3
PTEN mutation	Solid Tumor	PTEN mutation	Solid Tumor	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
RICTOR amplification	Lung Adenocarcinoma	RICTOR amplification	Lung Adenocarcinoma	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4
PTEN mutation + STK11 mutation	Breast Cancer	PTEN mutation + STK11 mutation	Breast Cancer	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4
PTEN mutation + TSC1 mutation	Leiomyosarcoma	PTEN mutation + TSC1 mutation	Leiomyosarcoma	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4
AKT1 mutation + mTOR mutation	Endometrial Cancer	AKT1 mutation + mTOR mutation	Endometrial Cancer	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4
AKT1 mutation + mTOR mutation	Breast Cancer	AKT1 mutation + mTOR mutation	Breast Cancer	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4
AKT1 mutation + mTOR mutation	Solid Tumor	AKT1 mutation + mTOR mutation	Solid Tumor	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4	CB-228 Sensitive: C4 – Case Studies CB-228 Sensitive : C4
BRAF mutation	Breast Cancer	BRAF mutation	Breast Cancer	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D
KRAS mutation	Breast Cancer	KRAS mutation	Breast Cancer	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D
RET mutation	Thyroid Gland Carcinoma	RET mutation	Thyroid Gland Carcinoma	CB-228 + AST-487 Sensitive: D – Preclinical CB-228 + AST-487 Sensitive : D	CB-228 + AST-487 Sensitive: D – Preclinical CB-228 + AST-487 Sensitive : D
RICTOR amplification	Small Cell Lung Cancer	RICTOR amplification	Small Cell Lung Cancer	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D
PIK3CA H1047R	Hepatocellular Cancer	PIK3CA H1047R	Hepatocellular Cancer	alpelisib + CB-228 Sensitive: D – Preclinical alpelisib + CB-228 Sensitive : D	alpelisib + CB-228 Sensitive: D – Preclinical alpelisib + CB-228 Sensitive : D

sapanisertib (CB-228)

Associations
(29)

Associations
(29)

sapanisertib (CB-228)

Associations(29)

Associations(29)

Associations
(29)

Associations
(29)